Glukokortikoidlere Bağlı Osteoporoz

Yıl 2019, Cilt: 11 Sayı: 3, 99 - 102, 03.05.2019

Kadriye Öneş

Öz

Sekonder osteoporozun en yaygın şekli olan glukokortikoid kaynaklı osteoporoz (GOP), önemli bir iyatrojenik problemi oluşturur. İlk aylarda %5 kemik kaybı meydana gelir. En fazla kırık vertebra, proksimal femur ve kostalarda görülür. GK kullanımı, kemik metabolizmasında önemli olan osteoblast ve osteoklast arasındaki dengeyi osteoklastlar lehine değiştirir. GK kullanımı kalsiyumun bağırsaklardan emilimini azaltmaktadır. Kalsiyumun renal alımında da azalma meydana gelir. Sonuçta kan kalsiyumunun azalması
paratiroid hormon salınımını stimüle ederek kemik rezorpsiyonunu artırır. Glukokortikoidlerin kemik sağlığı üzerindeki olumsuz etkilerini önlemek veya en aza indirmek için tedavi hemen başlanmalıdır. D vitamini, kalsiyum takviyeleri ve bifosfonatlar tedavide kullanılmalıdır.

Anahtar Kelimeler

Osteoporoz, Glukokortikoid, GK

Kaynakça

• 1. Diez-Perez A, Hooven FH, Adachi JD, et al. Regional differences in treatment for osteoporosis. The Global Longitudinal Study of Osteoporosis in Women (GLOW). Bone 2011; 49: 493–98.
• 2. Schakman O, Gilson H, Thissen JP. Mechanisms of glucocorticoidinduced myopathy. J Endocrinol 2008; 197: 1–10.
• 3. Weinstein RS. Glucocorticoid-induced osteonecrosis. Endocrine 2012; 41: 183–90.)
• 4. Van Staa TP, Leufkens HG, Cooper C. The epidemiology of corticosteroid-induced osteoporosis: a meta-analysis. Osteoporos Int 2002;13(10):777-87.
• 5. Seibel MJ, Cooper MS, Zhou H. Glucocorticoid-induced osteoporosis: mechanisms, management, and future perspectives. Lancet Diabetes Endocrinol. 2013 Sep;1(1):59-70.
• 6. Mazziotti G, Canalis E, Giustina A. Drug-induced Osteoporosis: Mechanisms and Clinical Implications.The American Journal of Medicine 2010; 123, 877-884.
• 7. Van Staa TP, Leufkens HG, Abenhaim L, Zhang B, Cooper C. Oral corticosteroids and fracture risk: relationship to daily and cumulative doses. Rheumatology (Oxford) 2000; 39: 1383–89.
• 8. De Vries F, Bracke M, Leufkens HG, Lammers JW, Cooper C, Van Staa TP. Fracture risk with intermittent high dose oral glucocorticoid therapy. Arthritis Rheum 2007;56 (1):208-14.
• 9. Civitelli R, Ziambaras K. Epidemiology of GCinduced osteoporosis. J Endocrinol Invest 2008;31(7 Suppl):2-6.
• 10. Olney RC. Mechanisms of impaired growth: effect of steroids on bone and cartilage. Horm Res 2009;72 Suppl 1:30-5.
• 11. Pennisi P, Trombetti A, Rizzoli R. Glucocorticoid-induced osteoporosis and its treatment. Clin Orthop Relat Res 2006;443:39-47.
• 12. De Nijs RN. Glucocorticoid-induced osteoporosis: a review on pathophysiology and treatment options. Minerva Med 2008;99:23-43.
• 13. Goemaere S, Liberman UA, Adachi JD, et al. Incidence of nonvertebral fractures in relation to time on treatment and bone density in glucocorticoid-treated patients: a retrospective approach. J Clin Rheumatol 2003; 9: 170–75.
• 14. Tatsuno I, Sugiyama T, Suzuki S, et al. Age dependence of early www.102 kliniktipdergisi.com symptomatic vertebral fracture with high-dose glucocorticoid treatment for collagen vascular diseases. J Clin Endocrinol Metab 2009; 94: 1671–77.
• 15. Ismail AA, Cooper C, Felsenberg D, et al. Number and type of vertebral deformities: epidemiological characteristics and relation to back pain and height loss. European Vertebral Osteoporosis Study Group. Osteoporos Int 1999; 9: 206–13.
• 16. Martin JC, Munro R, Campbell MK, Reid DM. Effects of disease and corticosteroids on appendicular bone mass in postmenopausal women with rheumatoid arthritis: comparison with axial measurements. Br J Rheumatol 1997;36:43-9.
• 17. Schousboe JT, Vokes T, Broy SB, et al. Vertebral fracture assessment: the 2007 ISCD official positions. J Clin Densitom 2008;11:92–108.
• 18. Markus J Seibel, Mark S Cooper, Hong Zhou. Glucocorticoid-induced osteoporosis: mechanisms, management, and future perspectives. Lancet Diabetes Endocrinol. 2013 Sep;1(1):59-70.
• 19. Jacobs JW, de Nijs RN, Lems WF, Geusens PP, Laan RF, Huisman AM, et al. Prevention of glucocorticoid induced osteoporosis with alendronate or alfacalcidol: relations of change in bone mineral density, bone markers, and calcium homeostasis. J Rheumatol 2007;34 (5):1051-7.
• 20. American College of Rheumatology Ad Hoc Committee on Glucocorticoid- Induced Osteoporosis Recommendations for the prevention and treatment of glucocorticoid-induced osteoporosis: 2001 update. Arthritis Rheum 2001;44:1496-503.
• 21. Lekamwasam S, Adachi JD, Agnusdei D, et al. A framework for the development of guidelines for the management of glucocorticoid- induced osteoporosis. Osteoporos Int 2012; 23: 2257–76.
• 22.Grossman JM, Gordon R, Ranganath VK, et al. American College of Rheumatology 2010 recommendations for the prevention and treatment of glucocorticoid-induced osteoporosis. Arthritis Care Res (Hoboken) 2010; 62: 1515–26.
• 23. Amin S, LaValley MP, Simms RW, Felson DT. The role of vitamin D in corticosteroid-induced osteoporosis: a meta-analytic approach. Arthritis Rheum 1999; 42: 1740–51.
• 24.Tang BM, Eslick GD, Nowson C, Smith C, Bensoussan A. Use of calcium or calcium in combination with vitamin D supplementation to prevent fractures and bone loss in people aged 50 years and older: a meta-analysis. Lancet 2007; 370: 657–66.
• 25. Sambrook PN. Corticosteroid osteoporosis: practical implications of recent trials. J Bone Miner Res 2000; 15: 1645–49.
• 26. Silverman SL, Lane NE. Glucocorticoid-induced osteoporosis. Curr Osteoporos Rep 2009;7:23-6.
• 27. Marcus R, Wong M, Heath H 3rd, Stock JL. Antiresorptive treatment of postmenopausal osteoporosis: comparison of study designs and outcomes in large clinical trials with fracture as an endpoint. Endocr Rev 2002; 23: 16–37.
• 28. Sambrook PN, Roux C, Devogelaer JP, et al. Bisphosphonates and glucocorticoid osteoporosis in men: results of a randomized controlled trial comparing zoledronic acid with risedronate. Bone 2012; 50: 289–95
• 29. Saag KG, Emkey R, Schnitzer TJ, et al. Alendronate for the prevention and treatment of glucocorticoid-induced osteoporosis. Glucocorticoid-Induced Osteoporosis Intervention Study Group. N Engl J Med 1998; 339: 292–99.
• 30. Cohen S, Levy RM, Keller M, et al. Risedronate therapy prevents corticosteroid-induced bone loss: a twelve-month, multicenter, randomized, double-blind, placebo-controlled, parallel- group study. Arthritis Rheum 1999; 42: 2309–18.
• 31. Reid DM, Devogelaer JP, Saag K, et al. Zoledronic acid and risedronate in the prevention and treatment of glucocorticoid-induced osteoporosis (HORIZON): a multicentre, double-blind, doubledummy, randomised controlled trial. Lancet 2009; 373: 1253–63.
• 32. Adachi JD, Bensen WG, Brown J, et al. Intermittent etidronate therapy to prevent corticosteroid-induced osteoporosis. N Engl J Med 1997; 337: 382–87
• 33. Lane NE, Sanchez S, Modin GW, Genant HK, Pierini E, Arnaud CD. Parathyroid hormone treatment can reverse corticosteroid- induced osteoporosis. Results of a randomized controlled clinical trial. J Clin Invest 1998; 102: 1627–33.
• 34. Saag KG, Shane E, Boonen S, et al. Teriparatide or alendronate in glucocorticoid-ind